Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report
Phase observationalN = 114
- Population
- Eligible patients with high-risk stage I non-seminomatous germ-cell tumours of the testis
- Design
- Prospective single-arm UK Medical Research Council study. Eligible patients were identified by the local histopathologist as having features confirmed in MRC surveillance studies to indicate an approximate 50% risk of relapse; central histopathology review was undertaken. Median follow-up 4 years, with 93 patients followed for at least 2 years.
- Arms
- BEP x 2 (experimental, n = 114): Two courses of cisplatin 100 mg/m2, bleomycin 30 mg weekly x 3 and etoposide 120 mg/m2 x 3, every 21 days
- People
- Cullen MH